Director Jonathan Freeman’s Dealings
Futura Medical, the innovative healthcare company focused on advanced transdermal technology has been notified that on 10 January 2017, Jonathan…
Pharmaceuticals, Biotechnology and Life Sciences
Futura Medical, the innovative healthcare company focused on advanced transdermal technology has been notified that on 10 January 2017, Jonathan…
Food allergy focused medical diagnostic company Omega has gotten ISO certification for the Quality Management System for its Asian subsidiary in India, and it started with the domestic sales of its products.
GENFIT, a biopharmaceutical company focused on developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that affect the liver…
Takeda has ensured the signature to buy USA-based drugmaker focused on producing cancer treatments, Ariad Pharmaceuticals for about $5.2 billion, or $24 per share in cash for stockholders.
Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.
Sareum Holdings, a drugmaker focused on cancer drugs on Monday announced cashing a $2.0 million milestone payment as part of the Chk1 licence agreement between its co-investment partner, the CRT Pioneer Fund, and Sierra Oncology, formerly known as ProNAi Therapeutics.
NeuroVive Pharmaceutical AB, the mitochondrial medicine company, has signed collaboration agreement with Karolinska Institutet, Stockholm, Sweden, regarding development of the company’s…
Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), has signed an distribution agreement…
Abivax said on Tuesday it would receive €8.4 million from “Projets de R&D Structurants Pour la Compétitivité” (PSPC) of the “Invest in the Future Program” (PIA).
European Commission has granted marketing authorisation for Novo Nordisk’s Fiasp for the treatment of diabetes in adults.